

PATENTS

Recent patent applications in vectors

Patent #	Subject	Assignee	Author	Date	Status
WO 9829431	Thiazide sensitive cotransporter, ATP-sensitive K channel and co-transporter genes; useful for developing products for the diagnosis and treatment of ion transport disorders, e.g., Gitelman's Syndrome or Bartter's Syndrome.	Yale Univ. (New Haven, CT)	Lifton RP, Simon DB	7/9/98	A1
WO 9829557	New ionic conjugate of particulate vector comprising hydrophilic core and polyanionic oligonucleotide; useful for, e.g., inhibiting gene expression in vitro or cell proliferation in vivo.	Biovector Therapeutics (Labege, France)	Betbeder D, de Miguel I, Jarvis T, Kravtsoff R, Pavco P, Sixou S	7/9/98	A1
WO 9829099	Mucosal administration of drugs, vaccines, etc., in biovector having natural polymeric core; provides nonspecific targeting to mucosa, good stability, controllable retention characteristics, and can be loaded immediately before use.	Biovector Therapeutics (Labege, France)	Betbeder D, de Miguel I, Etienne A; Kravtsoff R, Major M	7/9/98	A2
WO 9829102	New particulate vector with hydrophilic core and amphiphilic layer with same charge as core; used to transport and deliver active ingredients, e.g., proteins, nucleic acid, vaccines, etc., in pharmaceutical or cosmetic compositions or as food additives.	Biovector Therapeutics (Labege, France)	Betbeder D, Major M	7/9/98	A1
WO 9829533	Mutagenesis of mammalian genes using retroviral vectors comprising a splice acceptor sequence, a transcription termination sequence, and retroviral packaging and integration sequences.	Gaitanaris GA	Gaitanaris GA	7/9/98	A1
WO 9829554	Conferring resistance to herbicides that inhibit proto-porphyrinogen oxidase by introducing DNA that encodes a resistant form of the enzyme; also resistant plants and algae, mutant DNA, vectors, and transformed microorganisms.	Sumitomo Chem. Co. Ltd. (Tokyo); Duke Univ. (Durham, NC)	Boynton JE, Gillham NW, Ishige F, Randolph-Anderson BL, Sato R	7/9/98	A1
WO 9829437	Newly isolated equilibrative nucleoside transporter protein(s) and gene(s); used to develop products for treating disorder(s) associated with the transporter(s) and for use with nucleoside drug(s).	Univ. Alberta (Edmonton, Canada); Univ. Leeds (UK)	Baldwin SA, Cass CE, Young JD	7/9/98	A2
WO 9829441	New human galanin receptor, GALR2; useful for identifying agonists and antagonists to treat conditions involving galanin, e.g., for treatment of obesity or cognitive disorders.	Merck & Co. Inc. (Whitehouse Sta., NJ); Univ. Texas Health Sci. Center (San Antonio, TX); Univ. Toronto (Canada)	Kolakowski LF, O'Dowd B, Sullivan K	7/9/98	A1
WO 9829552	Serine-threonine kinase highly expressed in actively growing cells; useful for development of cell growth inhibitors and antitumor agents.	Chugai Res. Inst. Mol. Medicine (Tokyo)	Nezu J, Oku A	7/9/98	A1
WO 9829448	Human pathogenesis-related protein and related nucleic acids, transformed cells, antibodies, and agonists; useful in treatment, prevention, and diagnosis of cancer, infections, and neurological disease.	Incyte Pharm. (Palo Alto, CA)	Bandman O, Goli SK	7/9/98	A1
WO 9829432	<i>Mycobacterium</i> dihydrofolate reductase gene; useful for developing products for the prevention, diagnosis, and treatment of mycobacteria infections.	Southern Res. Inst. (Birmingham, AL)	Barrow WW, Dooley TP, Suling WJ, van Ginkel SZ	7/9/98	A1
US 5773705	Vector for expressing a protein in plants in the form of a fusion protein with ubiquitin, and plants containing this vector stably integrated in the genome; provides increased yields of proteins, e.g., pesticides or therapeutic agents.	Univ. Wisconsin Alumni Res. Found. (Madison, WI)	Callis J, Hondred D, Vierstra RD	6/30/98	A
US 5773274	Polynucleotide(s) encoding sulphotransferase enzyme, of human origin; useful for recombinant production of the enzyme and antisense control of the gene in vivo.	Takara Shuzo Ltd. (Shioga, Japan)	Honke K	6/30/98	A
US 5773252	New isolated fibroblast growth factor-15; used to develop products for, e.g., stimulating revascularization, treating wounds, preventing neuronal damage, or treating tumors or hypervascular diseases.	Human Genome Sciences (Rockville, MD)	Greene JM, Rosen CA	6/30/98	A
US 5773250	New isolated polynucleotide encoding response regulator polypeptide; used to develop products for the diagnosis, prevention, and treatment of, e.g., otitis media, conjunctivitis, pneumonia, bacteria, meningitis, emphysema, or endocarditis.	SmithKline Beecham (London; Philadelphia, PA)	Wallis NG	6/30/98	A
US 5772993	Therapeutic agent for use in the treatment of tumors; comprises recombinant adenovirus vector containing osteocalcin promoter for expression of toxic thymidine kinase.	Univ. Virginia Patent Found. (Charlottesville, VA)	Chung LWK, Kao C, Ko S, Sikes RA	6/30/98	A

Source: Derwent Information, Alexandria, VA. *The patents in the table are pending. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke St., Suite 250, Alexandria, VA 22314. Tel: 1 (800) DERWENT (info@derwent.com).